Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Genta has received notice that its patent application covering novel pharmaceutical gallium compositions and complexes has been allowed by the US Patent Office.
Subscribe to our email newsletter
The issued US patent extends the intellectual property surrounding the company’s franchise of oral gallium-containing products that are intended as potential treatment for diseases associated with accelerated bone loss.
The lead compound in this investigational pipeline, G4544, was developed in collaboration with Emisphere Technologies, and has completed its initial Phase I dose-ranging study.